Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice

Radiation Research

Volumn 181, Issue 5, 2014, Pages 445-451

  Lee, Chang Lung ^a   Lento, William E ^a   Castle, Katherine D ^a   Chao, Nelson J ^a   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 6 BROMOINDIRUBIN 3' OXIME; CHIR 99021; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE RADIATION SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HEMAPOIETIC ACUTE RADIATION SYNDROME; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SINGLE DRUG DOSE; WHOLE BODY RADIATION;

ACUTE RADIATION SYNDROME; AMINOPHENOLS; ANIMALS; APOPTOSIS; BONE MARROW; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; DRUG EVALUATION, PRECLINICAL; GLYCOGEN SYNTHASE KINASE 3; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; INDOLES; INJECTIONS, SUBCUTANEOUS; MALEIMIDES; MICE; MICE, INBRED C57BL; OXIMES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RADIATION INJURIES, EXPERIMENTAL; WHOLE-BODY IRRADIATION;

EID: 84901040280     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR13692.1     Document Type: Article

References (36)

1. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, et al. Animal models for medical countermeasures to radiation exposure. Radiat Res 2010; 173:557-78.
2. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140:1037-51.
3. Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30:513-28.
4. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1319-39.
5. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010; 6:309-22.
6. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. The hematologist and radiation casualties. Hematology 2003; 2003:473-96.
7. Plett PA, Sampson CH, Chua HL, Joshi M, Booth C, Gough A, et al. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 2012; 103:343-55.
8. Xiao M, Whitnall MH. Pharmacological countermeasures for the acute radiation syndrome. Curr Mol Pharmacol 2009; 2:122-33.
9. Mettler FA, Voelz GL. Major radiation exposure-what to expect and how to respond. N Engl J Med 2002; 346:1554-61.
10. Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 2006; 107:358-66.
11. Chen BJ, Deoliveira D, Spasojevic I, Sempowski GD, Jiang C, Owzar K, et al. Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. PLoS ONE 2010; 5:e11056.
12. Zhou D, Deoliveira D, Kang Y, Choi SS, Li Z, Chao NJ, et al. Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation. Int J Radiat Oncol Biol Phys 2013; 85:1141-48.
13. Doan PL, Himburg HA, Helms K, Russell JL, Fixsen E, Quarmyne M, et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med 2013; 19:295-304.
14. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HPH, et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med 2012; 18:1123-29.
15. Doble BW. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116:1175-86.
16. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006; 12:89-98.
17. Huang J, Zhang Y, Bersenev A, O'Brien WT, Tong W, Emerson SG, et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest 2009; 119:3519-29.
18. Ko KH, Holmes T, Palladinetti P, Song E, Nordon R, O'Brien TA, et al. GSK-3beta inhibition promotes engraftment of ex vivoexpanded hematopoietic stem cells and modulates gene expression. Stem cells 2011; 29:108-18.
19. Charvet C, Wissler M, Brauns-Schubert P, Wang SJ, Tang Y, Sigloch FC, et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Molecular Cell 2011; 42:584-96.
20. Woodgett J. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO 1990; 9:2431-38.
21. Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S, et al. Cooperation between both Wnt/fbetag-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 2011; 25:1928-42.
22. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of [beta]-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12:528-41.
23. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004; 25:471-80.
24. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. In vivo and in vitro stem cell function of c-kit-and Sca-1-positive murine hematopoietic cells. Blood 1992; 80:3044-50.
25. Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala D. GSK-3beta: A bifunctional role in cell death pathways. Int J Cell Biol 2012; 2012:930710.
26. Kirsch DG, Santiago PM, di Tomaso E, Sullivan JM, Hou WS, Dayton T, et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 2010; 327:593-6.
27. Thotala DK, Geng L, Dickey AK, Hallahan DE, Yazlovitskaya EM. A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys 2010; 76:557-65.
28. Thotala DK, Hallahan DE, Yazlovitskaya EM. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 2008; 68:5859-68.
29. Li B, Zhang C, He F, Liu W, Yang Y, Liu H, et al. GSK-3beta inhibition attenuates LPS-induced death but aggravates radiationinduced death via down-regulation of IL-6. Cell Physiol Biochem 2013; 32:1720-8.
30. Congdon KL, Voermans C, Ferguson EC, DiMascio LN, Uqoezwa M, Zhao C, et al. Activation of Wnt signaling in hematopoietic regeneration. Stem Cells 2008; 26:1202-10.
31. Hofmann C, Dunger N, Scholmerich J, Falk W, Obermeier F. Glycogen synthase kinase 3-beta: a master regulator of toll-like receptor-mediated chronic intestinal inflammation. Inflamm Bowel Dis 2010; 16:1850-8.
32. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6:777-84.
33. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7.
34. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320:226-30.
35. Shakhov AN, Singh VK, Bone F, Cheney A, Kononov Y, Krasnov P, et al. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of toll-like receptor 2 (TLR2). PloS ONE 2012; 7:e33044.
36. Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, Kandimalla ER, et al. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS ONE 2012; 7:e29357.